Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and H2O2-dependent chemodynamic therapy. (6th April 2022)
- Record Type:
- Journal Article
- Title:
- Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and H2O2-dependent chemodynamic therapy. (6th April 2022)
- Main Title:
- Autocatalytic oncotherapy nanosystem with glucose depletion for the cascade amplification of hypoxia-activated chemotherapy and H2O2-dependent chemodynamic therapy
- Authors:
- Hu, Yao
Bai, Song
Fan, Xingyu
Zhou, Fangfang
Chen, Botao
Tan, Songwen
Xu, Hui
Pan, Anqiang
Liang, Shuquan
He, Yongju - Abstract:
- Abstract : An autocatalytic nanosystem with glucose depletion for triple synergetic cancer starvation therapy, cascade amplified hypoxia-activated chemotherapy and enhanced H2 O2 -dependent chemodynamic therapy. Abstract : Employing hypoxia-activated prodrugs is an appealing oncotherapy strategy, but limited by insufficient tumor hypoxia. Moreover, a standalone prodrug fails to treat tumors satisfactorily due to tumor complexity. Herein, a nanosystem (TPZ@FeMSN-GOX) was established for triple synergetic cancer starvation therapy, hypoxia-activated chemotherapy and chemodynamic therapy (CDT). TPZ@FeMSN-GOX was prepared by synthesizing iron-doped mesoporous silica nanoparticles (FeMSNs) followed by surface conjugation with glucose oxidase (GOX), and then loading with hypoxia-activated prodrug tirapazamine (TPZ). When TPZ@FeMSN-GOX entered the tumor cells, GOX could not only exhaust glucose to starve cancer cells and concomitantly produce H2 O2, but also consume O2 to aggravate the hypoxia environment and amplify TPZ-mediated chemotherapy. Meanwhile, the released Fe 3+ was reduced to reactive Fe 2+ by endogenous glutathione, which ultimately decomposed the produced H2 O2 and endogenous H2 O2 into highly toxic ˙OH, guaranteeing highly efficient CDT. Together, TPZ@FeMSN-GOX could effectively kill cancer cells and significantly inhibit tumor growth, providing a good paradigm for effective tumor treatment.
- Is Part Of:
- Biomaterials science. Volume 10:Number 9(2022)
- Journal:
- Biomaterials science
- Issue:
- Volume 10:Number 9(2022)
- Issue Display:
- Volume 10, Issue 9 (2022)
- Year:
- 2022
- Volume:
- 10
- Issue:
- 9
- Issue Sort Value:
- 2022-0010-0009-0000
- Page Start:
- 2358
- Page End:
- 2369
- Publication Date:
- 2022-04-06
- Subjects:
- Biomedical materials -- Periodicals
610.28 - Journal URLs:
- http://pubs.rsc.org/en/journals/journalissues/bm ↗
http://www.rsc.org/ ↗ - DOI:
- 10.1039/d1bm01944a ↗
- Languages:
- English
- ISSNs:
- 2047-4830
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 2087.724000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 21596.xml